Share the Video:

Scaling the Infrastructure for FDA-Approved Psychedelics

Stacey Wallin, Jonathan Sabbagh, Steven Levine, Geoffrey Grammer

 Can FDA-approved psychedelic treatments scale without compromising quality? This panel explores a range of models shaping the future of care delivery. Hear from the innovators building the systems that could support broader access, improve outcomes, and reduce the burden on clinicians.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Related Videos

The Library is Open: A Conversation about Queer-Affirming Psychedelic Therapy

Terence Ching, Ph.D., Jessalyn Maguire, Justin Natoli, Shveta Mittal, PhD, Syre Saniyah, T Veiga, Jae Sevelius, Alan Davis

A Queer Path to Wellness: A Longitudinal Investigation of Ayahuasca’s Impact on LGBTQIA+ Psychological Health and Well-being

Matthew X Lowe

Women’s’ Biology and Psychedelics: Safety, Efficacy and Opportunity

Grace Blest-Hopley

Decoding the Menstrual Cycle: Empowering Women with Psychedelics and Data-Driven Research

Mia Cosco

The Impact of Psilocybin Use on Parenting: A Maternal Perspective

Amanda Elmore

Improving standardization and reducing bias in psychedelic drug development trials using an AI-enabled platform

Danielle Schlosser, Jennifer Tippett

Technology Across the Psychedelic Continuum

Matias Serebrinsky, Julie Simon, Danielle Schlosser, Lucia Huang

Scaling the Infrastructure for FDA-Approved Psychedelics

Stacey Wallin, Jonathan Sabbagh, Steven Levine, Geoffrey Grammer

Plant Power to the People: Healing Black and Melanated Minds and Souls

Imani Turnbull-Brown, Julian Fontaine Fox